Complications cardiaques de la COVID-19 en réanimation
#MMPMID32837211
Tran Van Nho J
; Pardo E
Prat Anesth Reanim
2020[Sep]; 24
(4
): 212-217
PMID32837211
show ga
The World Health Organization declared the SARS-CoV-2 infection causing severe
acute respiratory distress a global pandemic in March 2020. While respiratory
features are commonly at the forefront of the disease, cardiovascular
complications have been observed and associated with a poorer prognosis. The ACE2
enzyme intrinsically involved in the physiology of cardiac function and in the
development of hypertension and diabetes has been identified as a functional
receptor for SARS-CoV-2. It is difficult to highlight the precise mechanisms of
cardiac damage because of its possible multiple implications, through direct
damage from SARS-CoV-2 responsible for viral myocarditis or indirect damage from
the state of exacerbated systemic inflammation associated with hypoxaemia. The
treatments of the disease may also induce adverse effects such as an increase in
QT segment duration. Measurements of cardiac biomarkers are required if
myocardial damage is suspected and are part of a panel of arguments confronted
with clinical features, ultrasonic monitoring and electrocardiogram. As the
cardiac disorders increase post-hospital morbidity, risk stratification with
cardiac MRI and prolonged follow-up are required.
free
free
free
